(Q57088775)

English

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study

No description defined

Statements

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study (English)
0 references
0 references
0 references
0 references
D.J. Watkins
0 references
J. Thomas
0 references
J. Webb
0 references
Y. Barbachano
0 references
J. Oates
0 references
I. Chau
0 references
May 2014
0 references
50
0 references
8
0 references
1422-1429
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit